Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 4

recruiting
3 974
countries
28
conditions
2 106

44 trials match your criteria

Autoimmune haemolytic anaemia+1

Not recruiting

Study for Patients with Advanced Malignancies: Continued Treatment with Parsaclisib Alone or with Itacitinib, Ruxolitinib, Ibrutinib, or Tafasitamab

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib

Richter's syndrome

Not recruiting

Study on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Richter Transformation (RT)

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib

Waldenstrom's macroglobulinaemia+1

Not recruiting

Study on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Waldenstrom Macroglobulinemia Using a Drug Combination

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib

Mantle cell lymphoma+2

Not recruiting

Study on KTE-X19 CAR-T Cell Therapy for Patients with Relapsed or Refractory Mantle Cell Lymphoma Responding Partially to Ibrutinib

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Fludarabine

Waldenstrom's macroglobulinaemia

Not recruiting

Study on Carfilzomib and Ibrutinib for Patients with Waldenström’s Macroglobulinemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib

Waldenstrom's macroglobulinaemia

Not recruiting

Study on the Effectiveness of Bortezomib, Rituximab, and Ibrutinib for Patients with Newly Diagnosed Waldenström’s Macroglobulinemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib

Mantle cell lymphoma

Not recruiting

Study on Obinutuzumab, Venetoclax, and Ibrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib

Mantle cell lymphoma stage II+2

Not recruiting

Study on Ibrutinib and Drug Combination for Patients with Generalized Mantle Cell Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Ibrutinib

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.